Mirvetuximab Soravtansine for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 5 registered trials.

Why this status

  1. 16 Dec 2015: Trial registered, NCT02631876
  2. 2 Mar 2016: Trial started, NCT02631876
  3. 24 Dec 2019: Trial registered, NCT04209855
  4. 31 Dec 2019: Trial started, NCT04209855
  5. 5 Mar 2020: Trial registered, NCT04296890
  6. 23 Jul 2020: Trial started, NCT04296890
  7. 18 Aug 2022: Trial started, NCT05622890
  8. 21 Nov 2022: Trial registered, NCT05622890

The trials

NCT02631876: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

State
Completed
Phase
Phase 3
People
366 taking part
Started
2 Mar 2016
Primary completion
Jan 2019
Arms
Mirvetuximab Soravtansine
Results
Posted on the registry
  1. 16 Dec 2015: Trial registered
  2. 2 Mar 2016: Trial started
  3. 9 Jun 2020: Trial results posted

NCT04209855: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

State
Completed
Phase
Phase 3
People
453 taking part
Started
31 Dec 2019
Primary completion
6 Mar 2023
Arms
Mirvetuximab Soravtansine
Results
Posted on the registry
  1. 24 Dec 2019: Trial registered
  2. 31 Dec 2019: Trial started
  3. 1 Aug 2024: Trial results posted
  4. 29 Oct 2024: Trial completed

NCT04296890: A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

State
Completed
Phase
Phase 3
People
106 taking part
Started
23 Jul 2020
Primary completion
16 Nov 2021
Arms
Treatment
Results
Posted on the registry
  1. 5 Mar 2020: Trial registered
  2. 23 Jul 2020: Trial started
  3. 16 Nov 2022: Trial completed
  4. 7 Aug 2024: Trial results posted

NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

State
State not given
Phase
Phase 3
People
35 planned
Started
18 Aug 2022
Primary completion
30 Apr 2023
Arms
treatment
Results
None posted
  1. 18 Aug 2022: Trial started
  2. 21 Nov 2022: Trial registered

NCT06682988: A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

State
Under way
Phase
Phase 2
People
110 planned
Started
28 May 2025
Primary completion
Jul 2026
Arms
Randomized Phase 2 Cohort: Arm A, Randomized Phase 2 Cohort: Arm B, Hepatic Impairment Cohort : Mirvetuximab Soravtansine
Results
None posted
  1. 12 Nov 2024: Trial registered
  2. 28 May 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as TAK-853.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.